Biogen (NASDAQ:BIIB – Free Report) had its price target upped by Morgan Stanley from $231.00 to $238.00 in a research note issued to investors on Thursday,Benzinga reports. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock.
A number of other analysts have also recently commented on the company. Wall Street Zen cut Biogen from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Barclays increased their price objective on Biogen from $200.00 to $230.00 and gave the company an “equal weight” rating in a report on Wednesday. HSBC raised their price objective on Biogen from $165.00 to $175.00 and gave the stock a “reduce” rating in a research note on Thursday, September 10th. Wolfe Research upgraded Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective for the company in a research note on Thursday, August 13th. Finally, Royal Bank Of Canada lifted their target price on Biogen from $256.00 to $272.00 and gave the stock an “outperform” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $251.00.
Get Our Latest Stock Report on BIIB
Biogen Trading Up 1.6%
Shares of Biogen stock opened at $253.62 on Thursday. The firm’s 50 day simple moving average is $227.08 and its two-hundred day simple moving average is $201.04. The firm has a market capitalization of $37.49 billion, a price-to-earnings ratio of 108.38, a PEG ratio of 2.97 and a beta of 0.09. Biogen has a 12-month low of $146.52 and a 12-month high of $258.78. The company has a current ratio of 1.95, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39.
Biogen (NASDAQ:BIIB – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.63. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The firm had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.63 billion. During the same period in the previous year, the company earned $4.81 earnings per share. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. Analysts predict that Biogen will post 12.44 EPS for the current year.
Institutional Investors Weigh In On Biogen
Several hedge funds have recently added to or reduced their stakes in the business. Align Financial LLC grew its stake in Biogen by 339.3% during the 3rd quarter. Align Financial LLC now owns 123 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 95 shares in the last quarter. Bell Investment Advisors Inc purchased a new position in Biogen in the 2nd quarter worth approximately $27,000. Provenance Wealth Advisors LLC purchased a new position in Biogen in the 3rd quarter worth approximately $29,000. Canton Hathaway LLC purchased a new position in Biogen in the 3rd quarter worth approximately $31,000. Finally, Ashurst Perkins Coie Trust Co boosted its holdings in shares of Biogen by 92.2% during the 3rd quarter. Ashurst Perkins Coie Trust Co now owns 173 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 83 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.
Biogen News Roundup
Here are the key news stories impacting Biogen this week:
- Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
- Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
- Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
- Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
- Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
- Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.
About Biogen
Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.
The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.
Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Featured Stories
- Five stocks we like better than Biogen
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
